Patients with type 2 diabetes who received empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, were almost 40% less likely to have a kidney stone than patients who received a placebo during a median of 1.5 years of treatment. The findings are from an analysis of pooled data from phase 1-4 clinical trials of empagliflozin for blood […]
